Dec. 24th Beijing China


Shenogen’s Charlie Wang and Qingcong Lin were selected as members of Beijing Foreign Talents Recruiting (Haiju) Program.


Dr. Charlie Wang is a co-founder, Chief Science Officer & Member of Board of Directors of Shenogen Pharma Group. He received Ph.D. degree from Washington University at St. Louis. He completed postdoctoral training in Princeton University, and was Assistant Professor of Harvard Medical School. Dr. Wang was a professor of pathology in Creighton University, director of an oncology laboratory when he founded Shenogen together with Dr. Kun Meng. Dr. Wang has over 20-year experience in cancer research. He is expert in molecular cancer biology, especially cell proliferation, differentiation and apoptosis. Dr. Wang is dedicated to study breast cancer related genes. He identified and cloned a novel membrane estrogen receptor ER-alpha 36 and studied its functions. His findings greatly contributed to the understanding of the pathogenesis of breast cancer, and got high remarks from Elwood Jensen, fellow of National Academy of Sciences and V. Craig Jordan, “Father of Tamoxifen”. Dr. Wang received grants from NIH, American Cancer Society, the US Department of Defense and Susan G. Komen Foundation. Dr. Wang has authored/ co-authored more than 70 peer-reviewed papers, host and attended many key scientific conferences, written four books and owned three granted patents. Dr. Wang returned China in 2014. He was elected into the Recruitment Program of Global Experts, Beijing Haiju Program and Shandong Taishan Academician Program.


Dr. Qingcong Lin is Vice President of Shenogen Pharma Group, responsible for biologic drug development. Dr. Lin has extensive expertise in multiple drug R&D and therapeutic areas, including cell biology, molecular biology, molecular genetics, genetically engineered mouse tumor model, therapeutic antibody development, hybridoma antibody and human phage antibody library construction, antibody engineering, antibody humanization, affinity maturation and optimization, and mammalian antibody expression and production. Prior to joining Sheongen, He worked in Pfizer as a principal scientist and group leader of antibody engineering group. Before joining Pfizer, he worked in Wyeth and Harvard Medical School as Director of Genetic Engineering Lab of Genetics and Genomics Research Center. Dr. Lin got B.S. in Cell Biology and M.S. in Developmental Biology from Wuhan University. After graduating from Wuhan University, Dr. Lin started teaching in Nanjing University, during that period of time he did molecular biology research in Chinese Academy of Sciences, Shanghai Institute of Cell Biology as a visiting scientist in 1990. Dr. Lin received Ph.D. of Molecular Cell Biology from Albert-Einstein College of Medicine and completed postdoctoral training in Albert-Einstein College of Medicine and Harvard Medical School. He also got a M.S. of Computer Science from City University of New York in 2001. 


Ever since foundation, Shenogen has 3 members of Central Recruitment Program of Global Experts (Qianren), 7 members of Beijing Foreign Talents Recruiting Program (Haiju), 1 member of Beijing One Hundred Leaders Program (Lingjun) and 2 members of Beijing Science & Technology New Star Program.




About Shenogen

Shenogen Pharma Group is a drug discovery and development company based in Beijing, China, that dedicated the development of first-in-class therapeutics for cancer treatment. We possess robust intellectual property rights around a novel membrane-bound estrogen receptor, ER-alpha 36, which is related to tumor metastasis. Under the motto of “Better Medicine, Better Life” and a seasoned management team, together with our partners, Shenogen has developed an impressive product pipeline. Our pipeline consists of novel small molecule and antibody therapeutics for cancer treatment which includes liver cancer, breast cancer, other solid tumors and leukemia. Our lead molecule, icaritin, is currently completing Ph II clinical trial for treatment of advanced hepatocellular carcinoma.

(For more information, please visit


Shenogen’s Charlie Wang and Qingcong Lin selected as Members of Beijing Foreign Talents Recruiting (Haiju) Program